Download Curriculum Course Objectives 4-28-14

PHRC 5240 Pharmacodynamics IV
CO01: Describe the normal and patho-physiology of the system(s) to which discussed
CO01.01: Identify chemical mediators of nociception and inflammation following
damage to tissues
CO01.02: Describe the characteristics of pain fibers, including whether they mediate
"fast" vs. "slow" pain, whether they are polymodal or not, and their localization in
various body tissues
CO01.03: Outline the "circuitry" of the neospinothalamic and paleo-spinothalamic
pains pathways, including the type of pain they mediate and the function of each
pathway in pain perception
CO01.04: Contrast "nociceptive" vs. "neuropathic" pain
CO01.05: Identify the three major genes which code for endogenous opioids, and list
the specific opioid(s) that are products of each gene
CO01.06: Discuss the basic principles of immune system activation
CO01.07: Discuss the mechanisms of inflammation
CO01.08: Describe the main signaling pathways and the basic physiology of the
immune system (innate vs. adaptive) and of its activation
CO01.09: Outline and discuss the chemistry & pharmacology of the various classes
of prostanoids (prostaglandins-thromboxanes) and leukotrienes
CO01.10: Discuss the effects and role(s) in disease of the various classes of
prostanoids and leukotrienes
CO01.11: Discuss the basic principles of osteoarthritis (OA) pathophysiology
CO01.12: Describe the basic mechanisms of OA pathophysiology
CO01.13: Discuss the basic principles of gout pathophysiology
CO01.14: Describe the basic mechanisms of gout phathophysiology
CO01.15: Identify and describe differences in the drug therapeutic approaches for
acute vs. chronic gout
CO01.16: Discuss the basic principles of asthma pathophysiology
CO01.17: Describe the basic mechanisms of asthma pathophysiology
CO01.18: Identify and describe differences in the pharmacotherapeutic approaches
for acute asthma control vs. prophylactic asthma treatment
CO01.19: Discuss the basic principles of chronic obstructive pulmonary disease
(COPD) pathophysiology
CO01.20: Describe the basic mechanisms of COPD pathophysiology
CO01.21: Discuss the basic principles of pulmonary arterial hypertension (PAH)
pathophysiology
CO01.22: Describe the basic mechanisms of PAH pathophysiology
CO01.23: Identify bacterial species that frequently appear on antibiograms in terms
of morphology, gram staining, aerobic or anaerobic properties, infectious states, and
status as part of normal body flora
CO01.24: Define "MIC" and "MBC" and describe techniques used to obtain these
values
CO01.25: Compare the differences between "concentration-dependent" and "timedependent" killing of bacteria
CO01.26: Discuss the usefulness of the antibiogram
CO01.27: Discuss the mechanisms of resistance to the anti-infective agent
PHRC 5240 Pharmacodynamics IV
CO01.28: Outline the three stages of bacterial cell wall synthesis
CO01.29: Identify specific steps of bacterial cell wall synthesis that are inhibited by
antibiotics
CO01.30: Define "beta lactam" and be able to identify this moiety if it appears in the
structure of an antibiotic
CO01.31: Outline the de novo synthesis of folates in microorganisms
CO01.32: Outline the steps in microbial protein synthesis
CO01.33: Describe common pathogenic fungi and the disease-states associate with
these fungi (a list will be provided to the students by the instructor)
CO01.34: Identify a particular fungal specie as being a yeast, a mold, or dimorphic
CO01.35: Describe some of the common pathogenic non-HIV viruses for which
specific antiviral therapy is available
CO01.36: Outline the replication cycle of the HIV retrovirus especially with regard to
stages of the HIV life cycle that are inhibited by currently-available HIV antivirals
CO01.37: Describe the genomic structure of HIV-1, particularly with regard to the
gag, pol, and env genes and their gene products
CO02: Cite relevant pharmacokinetic/pharmacodynamic properties of the discussed drugs
CO02.01: Discuss narcotic analgesic in terms of: potency relative to morphine,
predominate opioid receptors activated/antagonized, routes of administration, oral-toparenteral ratio, adverse effects, indications, drug interactions & contraindications
CO02.02: Compare the pharmacological characteristics of the mu versus kappa
opioid receptor agonists
CO02.03: Compare the opioid receptor antagonists in terms of their half-lives and
oral bioavailabilities
CO02.04: Identify pharmacological therapies that are useful in the treatment of
neuropathic pain
CO02.05: Discuss the pharmacokinetics of NSAIDs
CO02.06: Discuss the pharmacokinetics of the various drug classes used in OA
pharmacotherapy
CO02.07: Discuss the pharmacokinetics of the various drug classes used in gout
pharmacotherapy
CO02.08: Discuss the pharmacokinetics of the various drug classes used in asthma
pharmacotherapy
CO02.09: Discuss the pharmacokinetics of the various drug classes used in COPD
pharmacotherapy
CO02.10: Discuss the pharmacokinetics of the various drug classes used in PAH
pharmacotherapy
CO02.11: State whether an antibiotic undergoes renal or biliary elimination(or both)
CO02.12: State whether an antibiotic agent is used orally or parenterally (or both)
CO03: Describe the mechanism of action of discussed drugs, including their specific
CO03.01: Outline the components of the descending analgesia circuit, including
endogenous mediators of the analgesic response
PHRC 5240 Pharmacodynamics IV
CO03.02: Explain the physiological mechanisms by which opioids are able to alter
neuro-transmission in pain circuits
CO03.03: List the major opioid receptor subtypes and discuss the corresponding
pharmacological effects that are mediated by activation of each receptor subtype
CO03.04: Cite and discuss the mechanisms of action and clinical uses of nonsteroidal anti-inflammatory drugs (NSAIDs)
CO03.05: Cite and discuss mechanisms of action of the various drug classes used
in OA pharmacotherapy
CO03.06: Cite and discuss the mechanisms of action and clinical uses of the various
drug classes used in (both acute and chronic) gout pharmacotherapy
CO03.07: Cite and discuss the mechanisms of action and clinical uses of the various
drug classes used in asthma pharmacotherapy (both for acute episode control and
for chronic, prophylactic treatment)
CO03.08: Cite and discuss the mechanisms of action and clinical uses of the various
drug classes used in COPD pharmacotherapy
CO03.09: Cite and discuss the mechanisms of action and clinical uses of the various
drug classes used in PAH pharmacotherapy
CO03.10: State the mechanism of action of an anti-infective agent
CO03.11: Describe the general antimicrobial spectrum of the agent
CO03.12: Cite special coverages (e.g., when the anti-infective agent is a drug of
choice for a particular microorganism)
CO04: Describe organ system effects of the discussed drugs
CO04.01: Describe the CNS and peripheral pharmacological effects of morphine
CO04.02: Describe opioid tolerance and dependence
CO05: Cite idiosyncratic and pharmacologically-based side effects of discussed drugs
CO05.01: Describe specific manifestations of opioid withdrawal
CO05.02: Discuss the side effects and contraindications of NSAIDs
CO05.03: Discuss the side effects and contraindications of the various drug classes
used in OA pharmacotherapy
CO05.04: Describe the side effects and contraindications of the various drugs used
in gout pharmacotherapy
CO05.05: Describe and discuss the side effects and contraindications of the various
drugs used in asthma pharmacotherapy
CO05.06: Describe and discuss the side effects and contraindications of the various
drugs used in COPD pharmacotherapy
CO05.07: Describe and discuss the side effects and contraindications of the various
drugs used in treating PAH
CO05.08: Describe the adverse effects of the anti-infective agent
CO06: Identify the clinical role of discussed drugs in therapy
CO06.01: Discuss the role of opioid antagonists in opioid overdose (detoxification)
and abuse prevention
CO06.02: Discuss the clinical uses of the various classes of prostanoids and
leukotrienes
PHRC 5240 Pharmacodynamics IV
CO06.03: Cite and discuss clinical uses of the various drug classes used in OA
pharmacotherapy
CO06.04: Identify and describe differences in the pharmacotherapeutic approaches
for the treatment of asthma vs. COPD
CO06.05: Cite the therapeutic uses of the anti-infective agent
CO07: Identify potential and known drug interactions
CO07.01: Discuss the interactions with other (non-NSAID) drugs and with other
NSAIDs
CO07.02: Discuss the interactions with other drugs and with each other of the
various drug classes used in OA pharmacotherapy
CO07.03: Describe and discuss the interactions with other drugs and with each
other of the various drugs used in gout pharmacotherapy
CO07.04: Cite and discuss the interactions with other drugs and with each other of
the various drug classes used in asthma pharmacotherapy
CO07.05: Cite and discuss the interactions with other drugs and with each other of
the various drug classes used in COPD pharmacotherapy
CO07.06: Cite and discuss the interactions with other drugs and with each other of
the various drug classes used in PAH pharmacotherapy
CO07.07: Discuss the drug interactions associated with the anti-infective agent, if
any
CO08: Cite contraindications associated with the use of a drug
CO08.01: Cite any contradictions to the use of the anti-infective agent